US FDA issues guidelines on imaging agents
This article was originally published in Clinica
Executive Summary
Manufacturers of contrast agents and radiopharmaceuticals used in medical imaging have three final guidances from the US FDA on how they should structure clinical trials and prepare premarket submissions. The three guidance notes cover such issues as conducting safety assessments, tailoring clinical trials so they focus on the agent's performance in diagnosing and monitoring specific diseases and conditions, the selection of trial subjects and the analysis of clinical trial data.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.